Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Teva’s new asthma therapy reslizumab accepted for EU review

Teva’s new asthma therapy reslizumab accepted for EU review

26th August 2015

Teva has had its new asthma drug reslizumab accepted for review by the European Medicines Agency (EMA).

A marketing authorisation application for reslizumab – a humanised anti-interleukin-5 monoclonal antibody for the treatment of inadequately controlled asthma – has been validated by the European regulator.

The drug is designed for patients with elevated blood eosinophils despite an inhaled corticosteroid-based regimen. Data from phase III trials has shown that it is able to deliver reduced asthma exacerbation rates and significantly improved lung function.

A final decision from the EMA on reslizumab is anticipated in the second half of 2016.

Robyn Hughes, brands director at Teva UK, said: "We are delighted with this successful filing for reslizumab, which, if approved, will broaden and strengthen our respiratory offering and provide a much-needed new treatment for an underserved patient group."

Earlier this month, the firm purchased a 51 percent equity share of the genomic analysis company Immuneering, a long-time collaborative partner, to further expand the capabilities of the business.ADNFCR-8000103-ID-801798747-ADNFCR

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.